Filtered By:
Cancer: HER2

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 260 results found since Jan 2013.

Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes
Conclusions: These findings show that, in the field of nucleic acid medicine, ZHER2-BNC/LP can be a useful carrier for siRNA delivery, and could also become a useful tool for gene silencing and to accomplish protein knock-down.
Source: Journal of Nanobiotechnology - June 24, 2013 Category: Nanotechnology Authors: Yuya NishimuraHiroaki MiedaJun IshiiChiaki OginoToshinobu FujiwaraAkihiko Kondo Source Type: research

The RhoA pathway mediates MMP‐2 and MMP‐9‐independent invasive behavior in a triple‐negative breast cancer cell line
Abstract Breast cancer is a heterogeneous disease that varies in its biology and response to therapy. A foremost threat to patients is tumor invasion and metastasis, with the greatest risk among patients diagnosed with triple‐negative and/or basal‐like breast cancers. A greater understanding of the molecular mechanisms underlying cancer cell spreading is needed as 90% of cancer‐associated deaths result from metastasis. We previously demonstrated that the Tamoxifen‐selected, MCF‐7 derivative, TMX2‐28, lacks expression of estrogen receptor α (ERα) and is highly invasive, yet maintains an epithelial morphology. ...
Source: Journal of Cellular Biochemistry - April 16, 2013 Category: Biochemistry Authors: Katerina D. Fagan‐Solis, Sallie Smith Schneider, Brian T. Pentecost, Brook A. Bentley, Christopher N. Otis, John F. Gierthy, Kathleen F. Arcaro Tags: Article Source Type: research

Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab
Abstract: The therapeutic potential of anticancer antibodies is limited by the resistance of tumor cells to complement-mediated attack, primarily through the over-expression of membrane complement regulatory proteins (mCRPs: CD46, CD55 and CD59). Trastuzumab, an anti- HER2 monoclonal antibody, approved for the treatment of HER2-positive breast and gastric cancers, exerts only minor complement-mediated cytotoxicity (CDC). Pertuzumab is a novel anti-HER2 monoclonal antibody, which blocks HER2 dimerization with other ligand-activated HER family members. Here, we explored the complement-mediated anti-tumor effects of trastuzum...
Source: Molecular Oncology - February 27, 2013 Category: Cancer & Oncology Authors: Srinivas Mamidi, Marc Cinci, Max Hasmann, Volker Fehring, Michael Kirschfink Tags: Papers Source Type: research

Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
Reis-Filho, C J Lord & A Ashworth
Source: Oncogene - January 21, 2013 Category: Cancer & Oncology Authors: K-K ShiuD WetterskogA MackayR NatrajanM LambrosD SimsI BajramiR BroughJ FrankumR SharpeC MarchioH HorlingsF ReyalM van der VijverN TurnerJ S Reis-FilhoC J LordA Ashworth Tags: HER2-positive breast cancer microarrays gene expression comparative genomic hybridization siRNA screens TFAP2C Source Type: research

WNT10B/β‐catenin signalling induces HMGA2 and proliferation in metastatic triple‐negative breast cancer
Abstract Wnt/β‐catenin signalling has been suggested to be active in basal‐like breast cancer. However, in highly aggressive metastatic triple‐negative breast cancers (TNBC) the role of β‐catenin and the underlying mechanism(s) for the aggressiveness of TNBC remain unknown. We illustrate that WNT10B induces transcriptionally active β‐catenin in human TNBC and predicts survival‐outcome of patients with both TNBC and basal‐like tumours. We provide evidence that transgenic murine Wnt10b‐driven tumours are devoid of ERα, PR and HER2 expression and can model human TNBC. Importantly, HMGA2 is specifically exp...
Source: EMBO Molecular Medicine - January 11, 2013 Category: Molecular Biology Authors: Peter Wend, Stephanie Runke, Korinna Wend, Brenda Anchondo, Maria Yesayan, Meghan Jardon, Natalie Hardie, Christoph Loddenkemper, Ilya Ulasov, Maciej S. Lesniak, Rebecca Wolsky, Laurent A. Bentolila, Stephen G. Grant, David Elashoff, Stephan Lehr, Jean J. Tags: Research Article Source Type: research